Posted 3/17/2024, 9:50:00 AM
Madrigal Wins FDA Approval for First Drug Treating Growing NASH Crisis
- Madrigal Pharmaceuticals won FDA approval for resmetirom, the first drug targeting the multibillion-dollar NASH market
- Resmetirom will be marketed as Rezdiffra and is expected to launch in April
- NASH is a growing health crisis projected to impact 98 million people globally by 2030
- While a massive potential market, diagnosing NASH can be challenging which may slow sales growth
- Madrigal stock has room to run but faces potential future competition from other drug makers